Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

DVA US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

DVA US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Davita Inc.(DVA US)

$174.56+0.490.28%Ext:$175.77+1.200.69%(After Hours · 00:31:08 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Davita Inc.(DVA US)

$174.56+0.490.28%Ext:$175.77+1.200.69%(After Hours · 00:31:08 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Davita Inc. — Company Profile

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Exchange
UN
CEO
Javier J. Rodriguez
Headquarters
Denver, CO, US
IPO Date
Oct 31, 1995
Employees
78,000
Website
www.davita.com

Key Metrics

Price
$178.69
Market Cap
$11.47B
Revenue (TTM)
$3.42B
Net Income (TTM)
$197.53M
EPS (TTM)
2.93
P/E (TTM)
14.68
P/B (TTM)
-15.18
Dividend Yield
0.00%
ROE (TTM)
-26.15%
ROA (TTM)
1.13%
Operating Margin
14.11%
Beta
0.07

Davita Inc. — Company Profile

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Exchange
UN
CEO
Javier J. Rodriguez
Headquarters
Denver, CO, US
IPO Date
Oct 31, 1995
Employees
78,000
Website
www.davita.com

Key Metrics

Price
$178.69
Market Cap
$11.47B
Revenue (TTM)
$3.42B
Net Income (TTM)
$197.53M
EPS (TTM)
2.93
P/E (TTM)
14.68
P/B (TTM)
-15.18
Dividend Yield
0.00%
ROE (TTM)
-26.15%
ROA (TTM)
1.13%
Operating Margin
14.11%
Beta
0.07

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Website
www.davita.com
Location
Denver, CO, US
Phone720 631 2100
Employees78,000
CEOJavier J. Rodriguez
IPO DateOct 31, 1995

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3.3K)

Expand
  • Form 4BERKSHIRE HATHAWAY INC29 Oct
  • 10-QQ3ended 30 Sept 202629 Oct
  • 8-KResults of Operations and Financial Condition29 Oct
  • Form 4Maughan David Paul24 Sep
  • Form 4Hollar Jason M.18 Aug
  • Form 4DESOER BARBARA J18 Aug
  • Form 4Schechter Adam H18 Aug
  • Form 4Moore Gregory J.18 Aug
  • Form 4Pullin Dennis W18 Aug
  • Form 4Schoppert Wendy Lee18 Aug
  • Form 4Arway Pamela M18 Aug
  • Form 4YALE PHYLLIS R18 Aug
  • Form 4BERKSHIRE HATHAWAY INC4 Aug
  • 10-QQ2ended 30 Jun 20264 Aug
  • 8-KResults of Operations and Financial Condition4 Aug
  • Form 4Waters Kathleen Alyce17 Jun
  • Form 4Rodriguez Javier17 Jun
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)17 Jun
  • Form 144Rodriguez Javier16 Jun
  • Form 144Waters Kathleen Alyce15 Jun

News

  • DaVita Expects Fewer Dialysis Treatments in Q4, but Higher Revenue per Visit Could Help Offset the Drop03:14AM
  • DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law12 Nov
  • Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses12 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA12 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA12 Nov
  • DaVita (NYSE:DVA) Shares Cross Above 200 Day Moving Average – What’s Next?12 Nov
  • DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy?11 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA10 Nov
  • DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript10 Nov
  • DaVita Sees Growth and Drug Savings Offsetting 2027 Reimbursement Pressure10 Nov
  • Lowey Dannenberg, P.C. is Investigating DaVita Inc. (NYSE: DVA) for Potential Violations of the Federal Securities Laws9 Nov
  • DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript9 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA5 Nov
  • Investors Heavily Search DaVita Inc. (DVA): Here is What You Need to Know5 Nov
  • Did You Lose Money on DaVita Inc. Stock? The Law Offices of Howard G.4 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA3 Nov
  • DaVita Inc. to Participate in Upcoming Investor Conferences3 Nov
  • Lost Money on DaVita Inc. Shares? The Law Offices of Frank R.3 Nov
  • DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y30 Oct
  • What DaVita (DVA) Said on Its Q3 Earnings Call30 Oct

Mentions in Filings

  • = Daniel Virnich, MD Chief Executive Officer • Joined STLN in 2020 as COO, CEO since 2023 • 20+ years of executive leadership and value - based care operations experience • Previously, served as President of <strong>DaVita</strong> Medical Group, Florida and Senior VP of Operations for Healthcare Partners in Southern California Rob Carter Chief Financial Officer • Joined STLN in 2021 as VP of Finance, CFO since 2024 • 15+ years of finance leadership experience in …
    Starling Oncology, Inc.Davita Inc.·EX-99.1 - 8-K/A - Regulation FD Disclosure·Q4 26·12 Nov
  • = Daniel Virnich, MD Chief Executive Officer • Joined STLN in 2020 as COO, CEO since 2023 • 20+ years of executive leadership and value - based care operations experience • Previously, served as President of <strong>DaVita</strong> Medical Group, Florida and Senior VP of Operations for Healthcare Partners in Southern California Rob Carter Chief Financial Officer • Joined STLN in 2021 as VP of Finance, CFO since 2024 • 15+ years of finance leadership experience in …
    Starling Oncology, Inc.Davita Inc.·EX-99.1 - 8-K - Regulation FD Disclosure·Q4 26·12 Nov
  • … to hemodialysis clinics, including dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Rockwell's customer mix is diverse, with most customer sales concentrations under 10%. <strong>DaVita Inc.</strong> ("DaVita"), a related party (see Note 11), represented approximately 7% of total revenues for each of the three and nine months ended September 30, 2026, and 12% and 17% of total revenues for the three and nine months e …
    ROCKWELL MEDICAL, INC.Davita Inc.·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … el form or other lesser substance is required by a Tenant's Lease, or if another estoppel form is customarily used by such Tenant or parent company of such Tenant, notwithstanding what is provided in such Lease (e.g., any <strong>DaVita</strong> affiliate), then such form or substance may be used and deemed acceptable for that Tenant) (the "Tenant Estoppel Certificates"), duly executed by each Tenant, dated no more than 60 days prior to the Closing Date, which is …
    National Healthcare Properties, Inc.Davita Inc.·EX-2.1 - 10-Q - Quarterly report Q3·Q3 26·5 Nov
  • <strong>DaVita</strong>, Inc., or DaVita, Fresenius Kidney Care Group LLC, or Fresenius, and U.S. Renal Care, or USRC, account for a vast majority of the dialysis population in the U.S. As a result of this concentration of dialysis facilities in large networks, treatment is usually driven by medical protocols that are implemented across the entire network of clinics. Dialysis organizations require large data sets to adopt medical protocols and often have lengthy …
    Akebia Therapeutics, Inc.Davita Inc.·10-Q - Quarterly report Q3·Q3 26·5 Nov
  • … r***” means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate). ***“Special Concentration Percentage”*** means, with respect to each of the following Obligors, (a) <strong>DaVita</strong>, Inc. and its Affiliates, 10.00%; (b) Heartland Dental Care and its Affiliates, 5.00%; and (c) Aspen Dental and its Affiliates, 5.00%; provided that the Special Concentration Percentage of any Obligor and its Affiliates s …
    HENRY SCHEIN INCDavita Inc.·EX-10.3 - 10-Q - Quarterly report Q3·Q3 26·3 Nov

Key Stats

Trading

Px/Chg 1D$178.69 / +1.33%
52 Wk H$0.00
52 Wk L$114.89
Avg Volume853.10K
Beta0.07
Mkt Cap11.47B
FD Mkt Cap11.38B

Float

Shrs Out/Float64.20M / 62.87M
Short Float0.07%
Days to Cover4.97
Stock Repurchased$396.31M

Current Valuation

EV25.77B
EV/EBITDA9.55
EV/Sales1.86
P/B-15.18
P/S0.83
FCF Yield1.91%
ROE-26.15%
ROA1.13%
Current Ratio1.42

Estimates

P/E14.68
Est P/E0.00
Est EPS2.41
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings32.1514.6818.3513.0556.6458.01
Price / Sales1.950.711.050.953.663.35
Price / Book Value17.7811.5512.01100.88-20.38-15.17
Price / Free Cash Flow22.278.568.518.3333.5652.37
ENTERPRISE VALUE METRICS
Enterprise Value25,403.021,317.925,111.525,460.429,368.125,757.2
Enterprise Value / Sales4.311.842.071.998.117.54
Enterprise Value / EBITDA22.1510.3710.829.3440.9239.31
Enterprise Value / EBIT30.8116.1115.9412.7255.3153.95

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.1%11,618.811,609.912,140.112,815.613,643.1
Gross Income25.9%3,646.43,400.33,820.44,217.03,684.2
EBITDA1.6%2,484.42,055.92,321.12,724.72,642.1
EBIT1.7%1,803.71,323.31,575.62,000.91,926.7
Net Income-6.5%978.5560.4691.5936.3746.8
EPS (Diluted)1.7%8.905.717.4210.739.51
BALANCE SHEET
Cash & ST Inv12.7%484.2321.8391.7846.0782.1
Total Assets52%17,121.516,928.316,893.617,285.317,480.1
Total Liabilities2.6%14,750.514,703.514,150.215,193.916,321.7
Total Shareholder Equity—755.5712.31,056.1121.1-651.1
CASH FLOW
Net Operating Cash Flow-58%1,930.91,564.62,059.02,022.01,886.5
Cap Ex-2.7%-641.5-603.4-568.0-555.4-575.9
Free Cash Flow40.9%1,289.4961.11,491.01,466.61,310.6

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)172.37
Basic Shares64.20
Market Cap11,066.2
Diluted Shares65.50
Fully Diluted Shares Outstanding65.50
Fully Diluted Market Cap11,290.9
+Consolidated Debt13,392.4
−In-the-Money Convertible Debt—
+Capital Leases2,623.3
+Operating Leases—
−Cash & Equivalents-495.6
−Short-term Investments-70.7
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest1,716.9
+Pension Liabilities—
Enterprise Value25,679.9

Segment data

Revenue

by Products and services

  • U S Dialysis And Related Lab Services100%

Related companies

Fresenius Medical Care AG

FMS US

Park Dental Partners, Inc.

PARK US

Cryo Cell International Inc

CCEL US

Pacific Health Care Organization Inc

PFHO US

Mangoceuticals, Inc.

MGRX US

BioRestorative Therapies, Inc.

BRTX US

Telemynd, Inc.

PSYC US

NewGenIvf Group Ltd

NIVF US

Ontrak, Inc.

OTRKQ US

AnTix Holdings, Inc.

IMTH US

American Renal Associates Holdings, Inc.

ARA B1

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Website
www.davita.com
Location
Denver, CO, US
Phone720 631 2100
Employees78,000
CEOJavier J. Rodriguez
IPO DateOct 31, 1995

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3.3K)

Expand
  • Form 4BERKSHIRE HATHAWAY INC29 Oct
  • 10-QQ3ended 30 Sept 202629 Oct
  • 8-KResults of Operations and Financial Condition29 Oct
  • Form 4Maughan David Paul24 Sep
  • Form 4Hollar Jason M.18 Aug
  • Form 4DESOER BARBARA J18 Aug
  • Form 4Schechter Adam H18 Aug
  • Form 4Moore Gregory J.18 Aug
  • Form 4Pullin Dennis W18 Aug
  • Form 4Schoppert Wendy Lee18 Aug
  • Form 4Arway Pamela M18 Aug
  • Form 4YALE PHYLLIS R18 Aug
  • Form 4BERKSHIRE HATHAWAY INC4 Aug
  • 10-QQ2ended 30 Jun 20264 Aug
  • 8-KResults of Operations and Financial Condition4 Aug
  • Form 4Waters Kathleen Alyce17 Jun
  • Form 4Rodriguez Javier17 Jun
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)17 Jun
  • Form 144Rodriguez Javier16 Jun
  • Form 144Waters Kathleen Alyce15 Jun

News

  • DaVita Expects Fewer Dialysis Treatments in Q4, but Higher Revenue per Visit Could Help Offset the Drop03:14AM
  • DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law12 Nov
  • Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses12 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA12 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA12 Nov
  • DaVita (NYSE:DVA) Shares Cross Above 200 Day Moving Average – What’s Next?12 Nov
  • DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy?11 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA10 Nov
  • DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript10 Nov
  • DaVita Sees Growth and Drug Savings Offsetting 2027 Reimbursement Pressure10 Nov
  • Lowey Dannenberg, P.C. is Investigating DaVita Inc. (NYSE: DVA) for Potential Violations of the Federal Securities Laws9 Nov
  • DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript9 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA5 Nov
  • Investors Heavily Search DaVita Inc. (DVA): Here is What You Need to Know5 Nov
  • Did You Lose Money on DaVita Inc. Stock? The Law Offices of Howard G.4 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA3 Nov
  • DaVita Inc. to Participate in Upcoming Investor Conferences3 Nov
  • Lost Money on DaVita Inc. Shares? The Law Offices of Frank R.3 Nov
  • DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y30 Oct
  • What DaVita (DVA) Said on Its Q3 Earnings Call30 Oct

Mentions in Filings

  • = Daniel Virnich, MD Chief Executive Officer • Joined STLN in 2020 as COO, CEO since 2023 • 20+ years of executive leadership and value - based care operations experience • Previously, served as President of <strong>DaVita</strong> Medical Group, Florida and Senior VP of Operations for Healthcare Partners in Southern California Rob Carter Chief Financial Officer • Joined STLN in 2021 as VP of Finance, CFO since 2024 • 15+ years of finance leadership experience in …
    Starling Oncology, Inc.Davita Inc.·EX-99.1 - 8-K/A - Regulation FD Disclosure·Q4 26·12 Nov
  • = Daniel Virnich, MD Chief Executive Officer • Joined STLN in 2020 as COO, CEO since 2023 • 20+ years of executive leadership and value - based care operations experience • Previously, served as President of <strong>DaVita</strong> Medical Group, Florida and Senior VP of Operations for Healthcare Partners in Southern California Rob Carter Chief Financial Officer • Joined STLN in 2021 as VP of Finance, CFO since 2024 • 15+ years of finance leadership experience in …
    Starling Oncology, Inc.Davita Inc.·EX-99.1 - 8-K - Regulation FD Disclosure·Q4 26·12 Nov
  • … to hemodialysis clinics, including dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Rockwell's customer mix is diverse, with most customer sales concentrations under 10%. <strong>DaVita Inc.</strong> ("DaVita"), a related party (see Note 11), represented approximately 7% of total revenues for each of the three and nine months ended September 30, 2026, and 12% and 17% of total revenues for the three and nine months e …
    ROCKWELL MEDICAL, INC.Davita Inc.·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … el form or other lesser substance is required by a Tenant's Lease, or if another estoppel form is customarily used by such Tenant or parent company of such Tenant, notwithstanding what is provided in such Lease (e.g., any <strong>DaVita</strong> affiliate), then such form or substance may be used and deemed acceptable for that Tenant) (the "Tenant Estoppel Certificates"), duly executed by each Tenant, dated no more than 60 days prior to the Closing Date, which is …
    National Healthcare Properties, Inc.Davita Inc.·EX-2.1 - 10-Q - Quarterly report Q3·Q3 26·5 Nov
  • <strong>DaVita</strong>, Inc., or DaVita, Fresenius Kidney Care Group LLC, or Fresenius, and U.S. Renal Care, or USRC, account for a vast majority of the dialysis population in the U.S. As a result of this concentration of dialysis facilities in large networks, treatment is usually driven by medical protocols that are implemented across the entire network of clinics. Dialysis organizations require large data sets to adopt medical protocols and often have lengthy …
    Akebia Therapeutics, Inc.Davita Inc.·10-Q - Quarterly report Q3·Q3 26·5 Nov
  • … r***” means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate). ***“Special Concentration Percentage”*** means, with respect to each of the following Obligors, (a) <strong>DaVita</strong>, Inc. and its Affiliates, 10.00%; (b) Heartland Dental Care and its Affiliates, 5.00%; and (c) Aspen Dental and its Affiliates, 5.00%; provided that the Special Concentration Percentage of any Obligor and its Affiliates s …
    HENRY SCHEIN INCDavita Inc.·EX-10.3 - 10-Q - Quarterly report Q3·Q3 26·3 Nov

Key Stats

Trading

Px/Chg 1D$178.69 / +1.33%
52 Wk H$0.00
52 Wk L$114.89
Avg Volume853.10K
Beta0.07
Mkt Cap11.47B
FD Mkt Cap11.38B

Float

Shrs Out/Float64.20M / 62.87M
Short Float0.07%
Days to Cover4.97
Stock Repurchased$396.31M

Current Valuation

EV25.77B
EV/EBITDA9.55
EV/Sales1.86
P/B-15.18
P/S0.83
FCF Yield1.91%
ROE-26.15%
ROA1.13%
Current Ratio1.42

Estimates

P/E14.68
Est P/E0.00
Est EPS2.41
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings32.1514.6818.3513.0556.6458.01
Price / Sales1.950.711.050.953.663.35
Price / Book Value17.7811.5512.01100.88-20.38-15.17
Price / Free Cash Flow22.278.568.518.3333.5652.37
ENTERPRISE VALUE METRICS
Enterprise Value25,403.021,317.925,111.525,460.429,368.125,757.2
Enterprise Value / Sales4.311.842.071.998.117.54
Enterprise Value / EBITDA22.1510.3710.829.3440.9239.31
Enterprise Value / EBIT30.8116.1115.9412.7255.3153.95

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.1%11,618.811,609.912,140.112,815.613,643.1
Gross Income25.9%3,646.43,400.33,820.44,217.03,684.2
EBITDA1.6%2,484.42,055.92,321.12,724.72,642.1
EBIT1.7%1,803.71,323.31,575.62,000.91,926.7
Net Income-6.5%978.5560.4691.5936.3746.8
EPS (Diluted)1.7%8.905.717.4210.739.51
BALANCE SHEET
Cash & ST Inv12.7%484.2321.8391.7846.0782.1
Total Assets52%17,121.516,928.316,893.617,285.317,480.1
Total Liabilities2.6%14,750.514,703.514,150.215,193.916,321.7
Total Shareholder Equity—755.5712.31,056.1121.1-651.1
CASH FLOW
Net Operating Cash Flow-58%1,930.91,564.62,059.02,022.01,886.5
Cap Ex-2.7%-641.5-603.4-568.0-555.4-575.9
Free Cash Flow40.9%1,289.4961.11,491.01,466.61,310.6

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)172.37
Basic Shares64.20
Market Cap11,066.2
Diluted Shares65.50
Fully Diluted Shares Outstanding65.50
Fully Diluted Market Cap11,290.9
+Consolidated Debt13,392.4
−In-the-Money Convertible Debt—
+Capital Leases2,623.3
+Operating Leases—
−Cash & Equivalents-495.6
−Short-term Investments-70.7
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest1,716.9
+Pension Liabilities—
Enterprise Value25,679.9

Segment data

Revenue

by Products and services

  • U S Dialysis And Related Lab Services100%

Related companies

Fresenius Medical Care AG

FMS US

Park Dental Partners, Inc.

PARK US

Cryo Cell International Inc

CCEL US

Pacific Health Care Organization Inc

PFHO US

Mangoceuticals, Inc.

MGRX US

BioRestorative Therapies, Inc.

BRTX US

Telemynd, Inc.

PSYC US

NewGenIvf Group Ltd

NIVF US

Ontrak, Inc.

OTRKQ US

AnTix Holdings, Inc.

IMTH US

American Renal Associates Holdings, Inc.

ARA B1